Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01214798
Other study ID # SecondQinhuangdao201010
Secondary ID
Status Completed
Phase N/A
First received October 2, 2010
Last updated October 4, 2010
Start date January 2008
Est. completion date April 2010

Study information

Verified date October 2010
Source The Second Hospital of Qinhuangdao
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Observational

Clinical Trial Summary

Traumatic sesamoid displacement of the first metacarpophalangeal joint can affect thumb function.


Description:

Although occurrence is rare, the mechanism of the displacement is commonly complex and varied. Understanding the mechanism is critical for treatment of the disorder. We herein present a locked thumb MCPJ caused by sesamoid displacement.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date April 2010
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Traumatic sesamoid displacement

Exclusion Criteria:

- Pathologic sesamoid disorder

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The Second Hospital of Qinhuangdao
See also
  Status Clinical Trial Phase
Completed NCT03702361 - Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease Phase 4
Completed NCT00405210 - Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer Phase 1
Completed NCT01325194 - CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis Phase 2
Completed NCT00803244 - Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma) Phase 3
Completed NCT00552461 - Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Phase 2
Terminated NCT01868243 - Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively Phase 2/Phase 3
Completed NCT01323894 - Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling N/A